NAD+ and Longevity: What the Research Actually Shows About Aging

Why NAD+ Declines With Age

NAD+ decline isn't caused by a single mechanism — it's a convergence of several age-related processes:

• Increased PARP activation: As DNA damage accumulates with age, PARP-1 and PARP-2 enzymes consume more NAD+ for DNA repair. Chronic inflammation and oxidative stress accelerate this consumption. In aging cells, PARP activity can consume a majority of the available NAD+ pool.
• CD38 upregulation: CD38 is an ectoenzyme that degrades NAD+. Its expression increases with age and chronic inflammation. Research suggests CD38 is the primary driver of age-related NAD+ decline in some tissues — potentially more significant than PARP consumption.
• Decreased NAMPT expression: NAMPT is the rate-limiting enzyme in the NAD+ salvage pathway (the recycling system that reclaims NAD+ from nicotinamide). NAMPT expression declines with age, reducing the cell's ability to regenerate its NAD+ supply.
• Sirtuin depletion cycle: As NAD+ falls, sirtuin activity decreases. Reduced SIRT1 activity leads to mitochondrial dysfunction, which generates more oxidative stress, which activates more PARPs, which consumes more NAD+ — creating a self-reinforcing decline.

NAD+, Sirtuins, and the Aging Hallmarks

The seven mammalian sirtuins (SIRT1–7) are NAD+-dependent deacetylases that regulate multiple hallmarks of aging:

All seven sirtuins require NAD+ as a co-substrate — they literally cannot function without it. When NAD+ drops, sirtuin activity drops proportionally. This means DNA repair slows, mitochondria become less efficient, inflammatory pathways activate, and metabolic regulation deteriorates. Restoring NAD+ levels reactivates sirtuins and, in animal models, reverses many of these age-related declines.

Ways to Boost NAD+: NMN, NR, IV Infusions, and Precursors

There are several strategies for raising NAD+ levels, each with different bioavailability, cost, and evidence bases:

What the Human Trials Actually Show

A comprehensive 2025 review in Nature Aging, bringing together over 25 NAD+ researchers from international institutions, summarized the state of human evidence:

• Blood NAD+ levels reliably increase with NMN and NR supplementation after a few weeks. This is well-established across multiple trials.
• Specific populations show benefits: Women with prediabetes showed improved insulin sensitivity in one NR trial. Parkinson's patients showed preserved neuronal mitochondrial function. Patients with ataxia-telangiectasia (a premature aging syndrome) showed improved neurological scores and immune cell counts with NR supplementation.
• Healthy population results are mixed: Some metabolic health trials in generally healthy adults have not replicated the dramatic improvements seen in animal models. The gap between mouse and human results remains significant.
• Safety is well-established: Both NMN and NR appear safe across all completed trials, with no significant adverse effects at standard doses (250–1,000 mg/day for NMN; 300–2,000 mg/day for NR).
• Large definitive trials are still in progress: Most completed trials have been small (20–100 participants) and short-term (4–12 weeks). The field is waiting for larger, longer studies to determine if NAD+ boosting translates to meaningful healthspan or lifespan extension in humans.

Practical Protocol: An Evidence-Based Approach

Based on current evidence, here's a reasonable approach for adults interested in NAD+ optimization:

1. Test your baseline: Intracellular NAD+ testing is now available through specialty labs (Jinfiniti, AgingSOS). While reference ranges are still being established, knowing your baseline helps track response to supplementation.
2. Start with oral NMN or NR: 500–1,000 mg/day of NMN or 300–1,000 mg/day of NR. Take in the morning — NAD+ has circadian effects, and evening dosing may disrupt sleep in some individuals. Choose a third-party tested brand (look for certificates of analysis).
3. Support the salvage pathway: Ensure adequate intake of tryptophan (protein-rich diet), niacin equivalents (B3), and magnesium (cofactor for NAD+ synthesis). Exercise also increases NAMPT expression, boosting the recycling pathway.
4. Consider CD38 inhibitors: Apigenin (found in chamomile and parsley) and quercetin have shown CD38-inhibiting activity in preclinical studies, which may reduce NAD+ degradation. Evidence is preliminary but the supplements are well-tolerated.
5. Retest at 8–12 weeks: If using intracellular NAD+ testing, recheck after 2–3 months to confirm levels are rising. Adjust dose based on response.

Who should be cautious: Cancer patients or those with active malignancies should consult their oncologist — NAD+ supports all rapidly dividing cells, including tumor cells. While no human trial has shown increased cancer risk from NAD+ supplementation, the theoretical concern exists based on the biology.